SCHEMBL898305

SCHEMBL898305

CCc1cc2c(cc1OS(=O)(=O)C(F)(F)F)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SRPK1 Q96SB4 9/20 0.65
SRPK2 P78362 7/20 0.63
ALK Q9UM73 17/20 0.62
EML4 Q9HC35 6/20 0.62
DYRK3 O43781 1/20 0.62
CLK1 P49759 1/20 0.62
CLK2 P49760 1/20 0.62
DYRK1A Q13627 1/20 0.62
DYRK2 Q92630 1/20 0.62
CLK4 Q9HAZ1 1/20 0.62
SRPK3 Q9UPE1 1/20 0.62
DYRK1B Q9Y463 1/20 0.62
KDR P35968 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29962665 0.89 SRPK1 (0.67) SRPK1SRPK2ALKEML4DYRK3
SCHEMBL897356 0.89 ALK (0.70) SRPK1ALK
SCHEMBL897656 0.89 ALK (0.60) SRPK1SRPK2ALK
SCHEMBL20366632 0.87 ALK (0.65) SRPK1SRPK2ALKEML4DYRK3
SCHEMBL27087513 0.86 ALK (0.53) SRPK1SRPK2ALKEML4DYRK3
SCHEMBL29940496 0.86 ALK (0.53) SRPK1SRPK2ALKEML4DYRK3
SCHEMBL7812557 0.86 SRPK1 (0.47) SRPK1SRPK2ALKEML4DYRK3
SCHEMBL897220 0.86 ALK (0.66) SRPK1ALK
SCHEMBL897390 0.86 ALK (0.77) SRPK1SRPK2ALKEML4DYRK3
SCHEMBL896718 0.85 ALK (0.60) SRPK1SRPK2ALKDYRK3CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 US disclosed
EP-3345903-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2019-10-09 EP disclosed
EP-2975024-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2018-03-28 EP disclosed
US-20160340308-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-24 US disclosed
US-9440922-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-09-13 US disclosed
EP-2975024-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-20 EP disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 US disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 US disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 US disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 SRPK1 3208/4885SRPK2 3230/4885ALK 1/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 SRPK1 3208/4885SRPK2 3230/4885ALK 1/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 SRPK1 3208/4885SRPK2 3230/4885ALK 1/4885
US-20160340308-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 SRPK1 3208/4885SRPK2 3230/4885ALK 1/4885
US-20150150845-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 SRPK1 3208/4885SRPK2 3230/4885ALK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.